QH103 Cell Therapy for Resistant Autoimmune Nerve and Brain Diseases
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Cancer, Eyes & vision, Immune system & allergy clinical trials.
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18–75 years old
- Have one of seven specific autoimmune nerve or brain diseases that is resistant to standard treatments
- Meet disability and symptom severity thresholds specific to your condition (measured by EDSS, mRS, MG-ADL, or similar scales)
- Have adequate blood cell counts, liver, kidney, heart, and blood clotting function
- Not be pregnant or breastfeeding; agree to use birth control for at least 6 months after treatment
- Not have active infections, cancer in past 5 years, hepatitis B/C, HIV, or certain psychiatric conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IMC-002 for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4+). It aims to see if IMC-002 is safe and effective at preventing attacks.
This trial tests a new cell therapy called C-CAR168 for people with autoimmune diseases affecting the brain and spinal cord, such as multiple sclerosis, neuromyelitis optica, autoimmune encephalitis, or stiff person spectrum disorder. It is for patients whose condition has not improved with standard treatments.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
This observational study follows people with various immune-related neurological conditions, such as multiple sclerosis, neuromyelitis optica, and autoimmune encephalitis. It aims to better understand these diseases and their progression over time.
This trial tests a new cell therapy called SYS6020 for people with multiple sclerosis that has not improved with standard treatments. The goal is to see if it can slow or stop the disease and improve symptoms.
This early-stage trial tests a new CAR-T cell therapy called HY001N for people with hard-to-treat neurological autoimmune diseases like NMOSD, myasthenia gravis, MS, and others. It aims to see if targeting B cells can help when standard treatments have failed.
Hear when a new Multiple Sclerosis (MS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.